Healthcare

washington -- The U.S. Consumer Product Safety Commission announced a voluntary recall of Bead Bazaar USA children's jewelry due to lead exposure.

Washington -- The U.S. Food and Drug Administration announced the nationwide recall of "Rize 2 The Occasion" and "Rose 4 Her" sexual supplements due to a health hazard.

Lausanne, Switzerland -- Swiss scientists announced an achievement in supercomputing simulations they say could vastly improve osteoporosis diagnosis and treatment.

Normally, issuing final approvals for Abbreviated New Drug Applications (ANDAs) at the FDA is just another day on the job. But the ANDA granted to Teva Pharmaceuticals (Nasdaq: TEVA) yesterday for its generic version of Johnson & Johnson 's (NYSE: JNJ) Risperdal must have stung just a little.

FDA-caused drug approval delays are never something for a drugmaker to be overjoyed about, but at least GlaxoSmithKline 's (NYSE: GSK) investors have a better idea of how long the wait will be. On Monday, the drugmaker announced that a vaccine highly important to its future likely won't need new clinical studies before it gets approved.

I admit it: I'm no sports nut. Still, I find an occasional game fun to watch, and I recently read a review of the Michael Lewis book Moneyball, which tells the story of how the Oakland A's grew so successful.

Merck (NYSE: MRK) and Schering-Plough (NYSE: SGP) are ending their joint venture.

Riddle me this. If your business aims to develop new "value-added services for ... desktop products and innovative online offerings ... [focusing] on both traditional and new markets across the globe, while embracing social networking and mobile technology trends," what's your first step to reach that goal?

Washington -- The U.S. Consumer Product Safety Commission announced a voluntary recall of two models of Hewlett-Packard fax machines due to a fire hazard.

Merck (NYSE: MRK) has given investors a lot of headaches lately. From Merck's and Schering-Plough 's (NYSE: SGP) problems with Vytorin and Zetia to its own issues with the drug formally known as Cordaptive, Merck's investors have had good reason to push the stock down 35% since the beginning of the year.

Good news! Good news for those who want go in for TB tests but are apprehensive and suspicious about the currently used lengthy method of testing.

Indianapolis -- Cymbalta has been racking up U.S. government approvals for a variety of uses since it was introduced as an anti-depressant in 2004, healthcare analysts say.

The money from CV Therapeutics ' (Nasdaq: CVTX) recently approved medical diagnostic compound Lexiscan keeps rolling in. On Tuesday, CVT announced that it had received a $10 million milestone payment as a result of the marketing launch of the drug.